Drug intelligence / Profile preview

KIN-113

Development stage: Preclinical
Lead developer: Kinimmune
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intratumoral

Overview

KIN-113 is an investigational, next-generation glatiramoid conjugated to a pathogen-associated molecular pattern (PAMP) under development by Kinimmune for the treatment of solid tumors. Part of the Kinnate™ series, KIN-113 is designed for localized administration to stimulate innate immune activation within the tumor microenvironment. By combining a tissue-retentive glatiramoid peptide with a PAMP, the therapy aims to engage pattern recognition receptors (PRRs) on local immune cells, promoting antigen presentation and a coordinated antitumor immune response while minimizing systemic toxicity. KIN-113 is currently in the discovery stage of development.

Targets

PRR (Pattern recognition receptors)

Beyond the preview

Go deeper on KIN-113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIN-113.

Explore the full profile